Pancreatic Cancer Research

ResearcherHarold C. Simmons Comprehensive Cancer CenterNo recent work listed

Molly A. Silvers

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5544-8329; OpenAlex author ID A5080877239. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 2 papers

Papers 3

  1. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. Co-author DOI 10.1002/jso.24624↗
  2. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. Co-author DOI 10.1074/jbc.m117.813923↗
  3. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone. First author DOI 10.1038/srep17066↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David A. Boothman · 3 shared papers, 2015–2017 · strength 0.17
  2. Muhammad Shaalan Beg · 2 shared papers, 2017 · strength 0.13
  3. Matthew E. Merritt · 2 shared papers, 2017 · strength 0.13
  4. Xiumei Huang · 1 shared paper, 2017 · strength 0.06
  5. Daniel A. Laheru · 1 shared paper, 2017 · strength 0.06
  6. Gaurab Chakrabarti · 1 shared paper, 2015 · strength 0.04
  7. Zachary Moore · 1 shared paper, 2015 · strength 0.04
  8. Stanton L. Gerson · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.